The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice-Reference-Cited by-同舟云学术

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

Published:2014-10-01 Issue:5 Volume:60 Page:1593-1606
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Pawlak Michal¹²³⁴,Baugé Eric¹²³⁴,Bourguet William⁵,De Bosscher Karolien⁶,Lalloyer Fanny¹²³⁴,Tailleux Anne¹²³⁴,Lebherz Corinna⁷,Lefebvre Philippe¹²³⁴,Staels Bart¹²³⁴

Affiliation:

1. European Genomic Institute for Diabetes; Lille France

2. INSERM UMR1011, F-59000; Lille France

3. University Lille 2; Lille France

4. Institut Pasteur de Lille; Lille France

5. CNRS UMR 5048, CBS; Montpellier France

6. Cytokine Receptor Lab, Nuclear Receptor Signaling Unit, VIB Department of Medical Protein Research; VIB, Ghent University; Ghent Belgium

7. Department of Internal Medicine I; University Hospital Aachen; Aachen Germany

Funder

COST Action

FEDER

French Ministry for Education and Research

Institut National de la Santï¿½ et de la Recherche Mï¿½dicale, European Genomic Institute for Diabetes

Rï¿½gion Nord-Pas de Calais

Publisher

Wiley

Subject

Hepatology

Reference43 articles.

1. The natural history of nonalcoholic fatty liver disease: a population-based cohort study;Adams;Gastroenterology,2005

2. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis;Takahashi;World J Gastroenterol,2012

3. Nonalcoholic fatty liver disease: from steatosis to cirrhosis;Farrell;Hepatology,2006

4. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists;Fruchart;Cardiovasc Diabetol,2013

5. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects;Cariou;Diabetes Care,2013

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic glucagon action: beyond glucose mobilization;Physiological Reviews;2024-07-01

2. Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease;Gut;2024-06-11

3. Anti-steatotic effects of PPAR-alpha and gamma involve gut-liver axis modulation in high-fat diet-fed mice;Molecular and Cellular Endocrinology;2024-05

4. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors;Cancer Research Communications;2024-04-18

5. Theabrownin alleviates nonalcoholic fatty liver disease by inhibiting the intestinal farnesoid X receptor–ceramide axis;Food Frontiers;2024-04-02